Veeranna Lolla is Director, Regulatory Affairs, Specialty Generics and Biosimilars at Sandoz Inc., where he leads regulatory strategies for complex generic and biosimilar products. With more than 30 years of pharmaceutical industry experience, including over 22 years in Regulatory Affairs, he has extensive expertise in global regulatory strategy, CMC development, and lifecycle management across a broad range of dosage forms and therapeutic areas.

Prior to joining Sandoz, Mr. Lolla held leadership positions at Teva Pharmaceuticals, Pii, Strides Pharma, Endo Pharmaceuticals, and Sun Pharmaceuticals, with responsibilities spanning Regulatory Affairs, Technical Services, Manufacturing, Quality Compliance, and Research & Development. Throughout his career, he has played a key role in advancing the development and approval of generic, specialty, and complex pharmaceutical products.

Mr. Lolla holds a Master’s degree in Pharmaceutical Sciences (Pharmaceutics) from Mangalore University, India, and is Regulatory Affairs Certified (RAC) by the Regulatory Affairs Professionals Society (RAPS).